## In the Claims

Claims 1 - 12 (Cancelled)

13. (Currently Amended) A method of inhibiting angiogenesis, tumor invasion, or formation of decreasing intratumoral vessels to inhibit growth of melanoma and pulmonary metastases in a mammal comprising:

administering to the mammal a therapeutically effective amount of a nucleic acid molecule comprising a polynucleotide sequence of SEQ ID NO. 1.

- 14. (Previously Presented) The method according to claim 13, wherein the nucleic acid molecule is inserted into an expression vector.
- 15. (Previously Presented) The method according to claim 14, wherein the nucleic acid molecule is present in cells transformed by said molecule in a manner to express all or part of a disintegrin domain *in vivo*.
- 16. (Currently Amended) The method according to claim 15, wherein the disintegrin domain is Met-420 to Glu-511 of SEQ ID NO. 1metargidin.
- 17. (Currently Amended) A method of treating eancermelanoma in a mammal comprising decreasing intratumoral vessels to inhibit growth of the melanoma by administering a therapeutically effective amount of a nucleic acid molecule comprising a polynucleotide sequence of SEQ ID No. 1.
- 18. (Previously Presented) The method according to claim 17, wherein the nucleic acid molecule is inserted into an expression vector.
- 19. (Previously Presented) The method according to claim 18, wherein the nucleic acid molecule is present in cells transformed by said molecule in a manner to express all or part of a disintegrin domain *in vivo*.

- 20. (Currently Amended) A method according to claim 19, wherein the disintegrin domain is Met-420 to Glu-511 of SEQ ID NO. 1metargidin.
- 21. (Currently Amended) A method of treating psoriasispulmonary metastases in a mammal comprising inhibiting the metatases by decreasing intratumoral vessels by administering a therapeutically effective amount of a nucleic acid molecule comprising a polynucleotide sequence of SEQ ID NO. 1.
- 22. (Previously Presented) The method according to claim 21, wherein the nucleic acid molecule is inserted into an expression vector.
- 23. (Currently Amended) The method according to claim [[22]]24, wherein the disintegrin domain is Met-420 to Glu-511 of SEQ ID NO. 1 metargidin.
- 24. (New) The method according to claim 22, wherein the nucleic acid molecule is present in cells transformed by said molecule in a manner to express all or part of a disintegrin domain *in vivo*.